55 dokter terbaik untuk pengujian mutasi KRAS, NRAS, BRAF di dunia

Dr. Yusuf Acikgoz adalah onkolog medis di Rumah Sakit Universitas Lokman Hekim Ankara. Beliau berspesialisasi dalam menangani kanker kompleks, termasuk keganasan paru-paru, payudara, dan hati. Beliau menyelesaikan fellowship di Ohio State University di Amerika Serikat. Dr. Acikgoz mengelola perawatan seperti kemoterapi, radioembolisasi, dan imunoterapi.

• Anggota American Society of Clinical Oncology (ASCO).
• Asisten Peneliti untuk uji klinis Fase III, termasuk studi CheckMate-649.
• Bersertifikat dalam Praktik Klinis yang Baik dan Perlindungan Subjek Manusia di Ohio State University.
• Melakukan prosedur diagnostik seperti biopsi, gastroskopi, dan tes penanda tumor.

Dr. Viola Fox adalah Kepala Dokter di Klinik Hematologi, Onkologi, dan Kedokteran Paliatif di BKZ Solingen. Klinik ini merupakan pusat kanker interdisipliner yang telah tersertifikasi. Dr. Fox adalah pakar terkemuka dalam terapi obat untuk penyakit tumor di Jerman dan Eropa. Dia memiliki lebih dari 15 tahun pengalaman di bidang ini.

Dia adalah anggota dari German Society of Oncology and Haemato-oncology (GDHO), German Association of Physicians, dan American Association for Cancer Research. Dr. Fox juga aktif dalam penelitian biologi molekuler. Karyanya mendukung kemajuan dalam pengobatan kanker dan diagnostik molekuler.

Bidang keahliannya meliputi kemoterapi, imunoterapi, terapi target, dan terapi radiasi. Dr. Fox dikenal karena metode-metodenya yang inovatif dan komitmen kuatnya terhadap perawatan pasien. Usahanya telah menghasilkan tingkat pemulihan yang tinggi dan pengakuan dari rekan-rekannya.

Dr. Muhammed Mustafa Atci adalah Profesor Madya Onkologi Medis di Liv Hospital Topkapı. Beliau berspesialisasi dalam pengobatan kanker usus besar, payudara, lambung, dan paru-paru. Sebelumnya, beliau menjabat sebagai Koordinator Pendidikan di Rumah Sakit Kota Prof. Dr. Cemil Taşcıoğlu. Dr. Atci adalah anggota American Society of Clinical Oncology (ASCO).

• Penulis 19 makalah yang ditinjau sejawat tentang kanker gastrointestinal, toraks, dan endokrin.
• Menerbitkan studi tentang hasil kelangsungan hidup untuk kanker usus besar stadium IIB di Journal of Chemotherapy.
• Meneliti biomarker prognostik menggunakan pemindaian PET/CT dan volume tumor metabolik.
• Menangani kasus onkologi kompleks di klinik universitas İstinye University.

Dr. Irfan Cicin adalah Profesor Onkologi Medis di Rumah Sakit İstinye University Liv Topkapı. Beliau berspesialisasi dalam menangani kanker kompleks, termasuk glioblastoma, kanker paru-paru, dan tumor pankreas. Beliau menjabat sebagai profesor di Fakultas Kedokteran Universitas Trakya. Dr. Cicin sebelumnya pernah bertugas sebagai dokter di Angkatan Udara Turki.

• Melakukan terapi sistemik seperti imunoterapi, kemoterapi, dan terapi hormon.
• Menangani berbagai kondisi termasuk kasus ginekologi, ortopedi, dan neuro-onkologi.
• Pakar dalam HIPEC dan kemoembolisasi untuk keganasan hati dan perut.
• Bekerja di rumah sakit universitas dengan 300 tempat tidur dan 33 departemen medis.

Dr. Auala Hubert memimpin Pusat Onkologi Gastrointestinal di Hadassah Medical Center. Beliau menggunakan pengujian mutasi KRAS, NRAS, dan BRAF untuk memandu terapi kanker tingkat lanjut.

• Memiliki sertifikasi spesialis dalam onkologi medis dan radioterapi
• Melakukan HIPEC – memberikan kemoterapi yang dipanaskan langsung ke dalam rongga perut
• Anggota komite Israel Society of Clinical Oncology untuk kanker gastrointestinal
• Menggunakan CyberKnife dan Brakiterapi untuk penargetan tumor yang presisi
• Memenuhi kualifikasi standar USMLE untuk praktik medis

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Yaacov Lawrence adalah Kepala Onkologi Radiasi di Sheba Medical Center. Beliau memiliki spesialisasi dalam terapi radiasi presisi dan neuro-onkologi. Dr. Lawrence adalah pelopor bedah radio pleksus celiac untuk manajemen nyeri kanker pankreas. Beliau memegang gelar FASTRO, salah satu penghargaan tertinggi di bidang spesialisasi beliau.

• Memimpin Program Kanker Gastrointestinal di Sheba Medical Center.
• Melakukan bedah radio stereotaktik untuk tumor otak dan kanker sistem saraf.
• Penulis lebih dari 280 publikasi ilmiah tentang protokol radiasi yang dipersonalisasi.
• Menyelesaikan pelatihan fellowship onkologi radiasi di Thomas Jefferson University.

Dr. Jair Bar adalah ahli onkologi toraks dan Wakil Direktur Pusat Kanker di Sheba Medical Center. Beliau berspesialisasi dalam mengobati kanker paru-paru sel tidak kecil stadium lanjut menggunakan imunoterapi yang dipersonalisasi dan perawatan bertarget. Dr. Bar memegang gelar PhD dalam Biologi Molekuler dan memimpin laboratorium penelitian yang berfokus pada resistensi imunoterapi.

• Ketua Kelompok Kanker Paru-Paru Israel.
• Bersertifikat dalam Onkologi Medis dan Radioterapi Onkologi.
• Merawat pasien di Sheba Medical Center, salah satu dari 10 rumah sakit terbaik di dunia.
• Menggunakan profil molekuler dan genetik untuk membuat rencana perawatan kanker yang tepat.

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

Prof. Beni Boursi adalah spesialis onkologi gastrointestinal di Sheba Medical Center. Beliau menggunakan pengujian mutasi KRAS, NRAS, dan BRAF untuk perencanaan terapi target.

• Terlatih dalam onkologi di University of Pennsylvania dan MD Anderson Cancer Center
• Sarjana akademik di Perelman School of Medicine di Amerika Serikat
• Mempublikasikan penelitian tentang respons obat pada pasien dengan mutasi BRAF V600
• Anggota Asosiasi Onkologi Klinis dan Radioterapi Israel
• Meneliti interaksi mikrobioma untuk meningkatkan respons pasien terhadap pengobatan kanker

Dr. Zulfu Sertkaya adalah profesor asosiasi dan androlog di Andro Expertise di Istanbul. Beliau memegang gelar FEBU dari Asosiasi Urologi Eropa. Dr. Sertkaya berfokus pada kesehatan pria, fungsi seksual, dan prosedur urologi estetika. Beliau merawat pasien di kliniknya dan melakukan operasi di rumah sakit afiliasi.

• Mendapatkan status Fellow of the European Board of Urology (FEBU).
• Spesialis dalam andrologi, kesehatan seksual pria, dan urologi estetika.
• Melakukan operasi implan penis dan varikokelektomi untuk infertilitas.
• Bekerja di klinik yang diakreditasi oleh Asosiasi Medis Turki.

Dr. Brenda Pastrana adalah ahli bedah onkologi di Rumah Sakit Galenia yang terakreditasi JCI di Cancún. Beliau berspesialisasi dalam kanker payudara, tiroid, dan sistem pencernaan. Dr. Pastrana memiliki sertifikasi dari CONACEM. Beliau meraih gelar kedokteran dari Universidad Autónoma de México.

• Melakukan mastektomi, reseksi hati, dan operasi kanker usus besar yang kompleks.
• Merawat pasien di fasilitas yang memegang Status Berlian dari Accreditation Canada.
• Dosen universitas di Universidad Anáhuac.
• Anggota Masyarakat Onkologi Meksiko (SMEO).

Profesor Eckhart Weidmann mengepalai departemen hematologi di Klinik Nordwest. Pengujian mutasi KRAS, NRAS, dan BRAF membantunya menentukan terapi yang tepat untuk kelainan darah.

• Berspesialisasi dalam mengobati kanker darah kompleks dan limfoma non-Hodgkin
• Memimpin departemen khusus di rumah sakit akademik besar di Jerman
• Berfokus pada terapi target berdasarkan profil mutasi genetik
• Anggota Masyarakat Hematologi dan Onkologi Medis Jerman (DGHO)

Dr. Elnur Sahibov adalah spesialis onkologi radiasi di Rumah Sakit Emsey. Beliau memberikan keahlian dalam layanan onkologi termasuk pengujian mutasi KRAS, NRAS, dan BRAF.

• Terlatih di Fakultas Kedokteran Universitas Marmara dalam onkologi radiasi
• Menyelesaikan spesialisasi medis antara tahun 2012 dan 2016
• Lulus dari program kedokteran berbahasa Inggris di Universitas Marmara
• Berpraktik di Rumah Sakit Emsey, pusat multispesialisasi swasta di Turki

Dr. Shruti Kate memimpin departemen onkologi di HCG Manavata Cancer Centre. Sebelumnya, beliau menjabat sebagai konsultan di Tata Memorial Hospital yang bergengsi.

• Spesialis tumor padat dan kanker anak yang memerlukan pengujian mutasi KRAS, NRAS, dan BRAF
• Mempresentasikan penelitian kanker paru-paru pada World Conference on Lung Cancer 2018 di Toronto
• Pemenang penghargaan perjalanan dari International Association for the Study of Lung Cancer
• Anggota American Society of Clinical Oncology dan European Society for Medical Oncology
• Pakar dalam penggunaan imunoterapi dan terapi metronomik untuk stadium kanker lanjut

Dr. Hamza Ugur Bozbey adalah seorang ahli onkologi klinis di Uniqacare Clinic, Istanbul. Beliau menangani keganasan termasuk glioblastoma, sarkoma, dan kanker paru-paru stadium 4. Beliau menangani tumor padat dan kanker hematologi seperti leukemia dan limfoma, serta kondisi langka seperti kordoma dan tumor neuroendokrin.

• Menangani kanker ginekologi, ortopedi, dan neurologi.
• Menggunakan kemoterapi dan terapi target untuk penyakit metastasis stadium 4.
• Bekerja di Uniqacare Clinic, yang melayani lebih dari 430.000 pasien setiap tahun.
• Anggota Asosiasi Medis Turki.

Dr. Raj Nagarkar telah melakukan lebih dari 50.000 operasi kanker. Beliau memimpin HCG Manavata Cancer Centre, di mana pengujian mutasi KRAS, NRAS, dan BRAF memandu perencanaan bedah.

• Menyelesaikan residensi bedah onkologi di Tata Memorial Hospital di Mumbai
• Anggota Royal College of Surgeons of Edinburgh
• Berpartisipasi dalam lebih dari 200 uji klinis fase 1–3
• Profesor Bedah Onkologi (DNB) – melatih ahli bedah kanker masa depan
• Menangani kasus kompleks kanker hati, pankreas, dan kolorektal

Dr. Shaunak Valame adalah onkolog medis di HCG Manavata Cancer Centre. Ia berspesialisasi dalam onkologi molekuler untuk memandu pengujian mutasi KRAS, NRAS, dan BRAF untuk terapi target.

• Meraih DNB dalam Onkologi Medis dari rumah sakit bergengsi Indraprastha Apollo Hospital
• Mempresentasikan penelitian kanker lambung di Simposium Kanker Gastrointestinal ASCO di San Francisco
• Anggota American Society of Clinical Oncology (ASCO)
• Mantan dosen untuk International Winter School of Oncology di AIIMS Bhopal
• Menyediakan pengobatan presisi untuk kanker paru-paru, payudara, dan gastrointestinal